Improved biological activity of a mutant endostatin containing a single amino-acid substitution by Yokoyama, Y & Ramakrishnan, S
Improved biological activity of a mutant endostatin containing a
single amino-acid substitution
Y Yokoyama
1 and S Ramakrishnan*,1,2,3
1Department of Pharmacology, University of Minnesota, 6-120 Jackson Hall, 321 Church Street, S.E., Minneapolis, MN 55454, USA;
2Obstetrics and
Gynecology, University of Minnesota, Minneapolis, MN, USA;
3Comprehensive Cancer Center, University of Minnesota, Minneapolis, MN, USA
Human endostatin has an internal Asn-Gly-Arg (NGR) motif at position 126–128 following a proline at position 125. Asn-Gly-Arg-
containing peptides have been shown to target tumour vasculature and inhibit aminopeptidase N activity. We previously compared
the in vitro and in vivo biological activities of native endostatin and endostatin with a proline to alanine mutation (P125A-endostatin).
P125A-endostatin exhibited greater inhibition of both endothelial cell proliferation and human ovarian cancer growth compared to
native endostatin. Here we explore further the effects on biological activity of the P125A mutation, and show that aminopeptidase N
is not involved. To determine whether the increased biological activity of the mutant was due to unmasking of downstream NGR-
sequence, effect of endostatin on aminopeptidase N activity was investigated. Neither the native nor the P125A-endostatin inhibited
aminopeptidase N. However, synthetic peptides consisting of the S118-T131 region of endostatin inhibited aminopeptidase N. These
results suggest that the internal NGR site in native or mutant endostatin is not accessible to aminopeptidase N, and that this activity is
not involved in the enhanced biological activity of the P125A form. P125A-endostatin bound to endothelial cells more efficiently than
native endostatin and exhibited greater inhibition of not only proliferation but also migration of endothelial cells. P125A-endostatin
also localised into tumour tissue to a higher degree than the native protein, and displayed greater inhibition of growth of colon cancer
in athymic mice. Both proteins inhibited tumour cell-induced angiogenesis effectively. Real-time PCR analysis showed that both native
and P125A-endostatin decreased expression of key proangiogenic growth factors. Vascular endothelial growth factor and
angiopoietin 1 were downregulated more by the mutant. These studies suggest that the region around P125 can be modified to
improve the biological activity of endostatin.
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Endostatin is a proteolytic fragment of the noncollagenous domain
of collagen type XVIII (O’Reilly et al, 1997), a component of the
basement membrane. Endostatin inhibits growth factor-induced
proliferation and migration of endothelial cells in vitro and
angiogenesis in vivo. A number of independent studies have shown
that endostatin treatment inhibits tumour growth by blocking
angiogenesis (Boehm et al, 1997; O’Reilly et al, 1997; Dhanabal
et al, 1999). Endostatin binds to at least two distinctive sets of
molecules on the endothelial cell surface, a5b1/avb3 integrin (Rehn
et al, 2001; Wickstrom et al, 2002) and glycosyl-phosphatidylino-
sitol (GPI) anchored heparin sulphate proteoglycan (HSPG), or
glypican (Karumanchi et al, 2001). Glypican is believed to
sequester endostatin and present it to the integrins, thereby
forming a receptor-signalling complex. Binding to integrins is
linked to phosphorylation of SH2 containing Shb adaptor protein,
which is implicated in the apoptotic cascade (Dixelius et al, 2000).
Such interactions can activate intracellular signalling leading to
inhibition of endothelial cell proliferation and migration (Rehn
et al, 2001; Shichiri and Hirata, 2001). A recent study showed that
wnt-signalling pathways might also be modulated by endostatin
(Hanai et al, 2002). In addition to these direct actions, endostatin
has been shown to bind and inactivate metalloproteinases in vitro
(Kim et al, 2000). These studies collectively imply that the
mechanism of endostatin action is diverse and complex. Under-
standing the structure/function of endostatin therefore will help in
improving its efficacy to inhibit tumour growth.
Human endostatin containing a point mutation at position 125
has been identified during expression cloning (Yokoyama and
Ramakrishnan, 2002). Proline 125 is followed by a tripeptide, Asn-
Gly-Arg (NGR), a sequence that is known to target endothelial cells
(Pasqualini et al, 2000). In fact, chemical linkage of doxorubicin to
NGR peptides inhibited tumour growth efficiently (Arap et al,
1998). Asn-Gly-Arg sequence has also been shown to bind and
inhibit aminopeptidase N localised on vascular endothelial cells of
tumours. The P125A-mutation is not a conservative change and
would be expected to alter peptide folding around the mutation
site. However, we were able to express P125A-endostatin in yeast
in fully soluble form, and showed that it has similar gross
secondary structures as native endostatin. P125A-endostatin
inhibited in vitro endothelial cell proliferation and in vivo growth
of ovarian cancer more effectively when compared to native
endostatin (Calvo et al, 2002).
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native and P125A-endostatin. We report that the mutant protein
binds more effectively to endothelial cells and is more effective in
inhibiting not only endothelial cell proliferation but also migration
in vitro. P125A-endostatin also displayed improved inhibition of
colon cancer growth in athymic mice, and greater downregulation
of human vascular endothelial growth factor (VEGF) and human
angiopoietin 1 (Ang1) from tumours. Neither native nor mutant
endostatin inhibited aminopeptidase N activity. These studies
suggest that structural changes in endostatin can be used to
improve the biological activity of human endostatin.
MATERIALS AND METHODS
Cell lines and culture conditions
Bovine adrenal gland capillary endothelial (BCE) cells were
obtained from Clonetics Inc. (San Diego, CA, USA). Culture
conditions of human umbilical vein endothelial cells (HUVEC)
have been published previously (Ramakrishnan et al, 1996).
Human colon carcinoma cell line, LS174T, was obtained from
American Type Culture Collection (ATCC, Rockville, MD, USA).
LS174T cells were cultured in RPMI-1640 (GIBCO BRL, Gaithers-
burg, MD, USA) supplemented with 10% FBS, 100Uml
 1
penicillin, 100mgml
 1 streptomycin and 2mML -glutamine.
Cloning, expression and purification of mutant human
endostatin
The following primers were used to amplify the C-terminal end of
collagen type XVIII (183 amino acid residues) by RT–PCR:
Up: GGGGAATTCCACAGCCACCGCGACTTCCAG,
Down: GGGGCGGCCGCCTACTTGGAGGCAGTCATGAAGCT.
The PCR product was cloned into pPICZ-aA vector (Invitrogen,
Carlsbad, CA, USA) and sequenced. Selected clones were electro-
porated into X-33 host strain of Pichia pastoris (Invitrogen).
Previously published methods were followed for expression and
purification of endostatin (Yokoyama et al, 2000).
Structural analysis by circular dichroism
Circular dichroism (CD) studies of endostatin and P125A-
endostatin were carried out in a JASCO J-710 spectropolarimeter.
Protein samples were prepared in PBS at a concentration of
100mgml
 1. Path length of the cell was 0.1cm. Circular dichroism
spectra and molar ellipticity were obtained over the wavelength
range of 195–260nm.
Cell attachment assay
The method of cell attachment assay described previously was
used (Maeshima et al, 2000). A measure of 1nmolewell
 1 of
endostatin preparations or 0.2% gelatin were used to coat 96-well
plates. Human umbilical vein endothelial cells were prelabelled
with a vital, fluorescence dye, 5mM 5-(and-6)-carboxyfluorescein
diacetate, succinimidyl ester (5(6)-CFDA) (Molecular Probes,
Eugene, OR, USA) for 10min at 371C. Cells were added to wells
at a density of 40000cellswell
 1. After 1h incubation at 371C,
unbound cells were removed, and fraction of bound cells was
determined by a fluorescence plate reader (Cyto Fluor II;
PerSeptive Biosystems, Framigham, MA, USA) (excitation,
485nm, emission, 530nm).
Aminopeptidase N activity
Aminopeptidase N activity was determined by the method
described previously (Arap et al, 1998). Human umbilical vein
endothelial cell lysate (10mg protein) was used as a source of
aminopeptidase N and incubated with 0.225mg (0.9mmol)
substrate in a reaction buffer in the presence and absence of
inhibitors at 371C for 2h. Aminopeptidase N activity was detected
by absorbance at 405nm.
Endothelial cell proliferation assay
Essentially, the method described previously was used to
determine the effect of endostatin on BCE cell proliferation
(O’Reilly et al, 1997) by 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-
2,4-tetrazolium bromide, MTT (Carmichael et al, 1987; Yoon et al,
1999).
Endothelial cell migration assay
The migration of endothelial cells was determined by using Boyden
chambers (Neuro Probe, Gaithersburg, MD, USA) as previously
described (Dhanabal et al, 1999).
Tumour localisation
LS174T cells were injected subcutaneously at right and left sides of
the flanks of athymic nude mice. Tumour size reached about
500mm
3 on day 10. Tumour-bearing mice were randomised into
two groups. Endostatin or P125A-endostatin was injected at a dose
of 20mgkg
 1 subcutaneously. Tumour tissues and representative
normal tissues were surgically removed after 19h. This time point
was chosen to minimise overwhelming serum levels from
obscuring the tissue-bound endostatin. For comparison, serum
samples were also collected from the mice. Tissues were snap
frozen, and homogenised in RIPA buffer containing proteinase
inhibitors (PBS, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS,
10mgml
 1 PMSF), maintained at 41C for 45min, and cleared by
centrifugation. Human endostatin concentrations in serum and
tissue lysates were measured using an enzyme-linked immunoas-
say (Cytimmune, College park, MD, USA) according to the
manufacturer’s instructions. Statistical significance was deter-
mined by Student’s t-test.
Matrigel plug assay
Matrigel plug assay was used to determine inhibition of tumour
cell-induced angiogenesis in vivo (Zhang et al, 2000). LS174T cell
suspension was mixed with matrigel, and injected into nude mice
subcutaneously. Mice were treated with native endostatin or
P125A-endostatin at a dose of 20mgkg
 1day
 1 subcutaneously at
a distant site near the neck. Control mice were treated with an
equal volume of sterile PBS at similar schedule. Treatment was
started just after the matrigel implantation and continued for 1
week. At 1 day after the last treatment, the matrigel was removed.
A part of the matrigel was used to prepare cryostat sections and
another part of the samples was used for Real-time PCR analysis.
Frozen sections (10mm) of matrigel were stained with 1:50
dilution of an anti-CD31 monoclonal antibody conjugated to
phycoerythrin (MEC 13.3, BD PharMingen, San Diego, CA, USA)
and analysed for vessel density (Wild et al, 2000). Serial frozen
sections were used to localise VEGF by indirect immunofloures-
cence method using a polyclonal antiserum made against
recombinant human VEGF165 (Olson et al, 1996). Another part
of the matrigel samples were fixed in 10% neutral buffered
formalin and processed for haematoxylin and eosin (H&E)
staining.
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Total RNA was extracted from frozen matrigel samples using the
RNeasy Mini kit (Qiagen, Valencia, CA, USA) according to the
manufacturer’s protocol. Reverse transcription was performed
with the SuperScript II kit (Invitrogen) using 1mg of total RNA.
Real-time PCR was carried out by using SYBR Green PCR Master
Mix (Applied Biosystems, Foster City, CA, USA) in an ABI PRISM
7700 sequence detection system (Applied Biosystems) (TaqMan).
Primer sequences described by Gerber et al (2000) were used
(Table 1) to amplify proangiogenic factors related messages from
the human tumour cells and relevant target receptors on
endothelial cells of mouse origin. Following conditions were
used for PCR: 501C for 2min, 951C for 10min, and 40 cycles at
951C for 0.15min, 601C for 1min. Negative controls included
omission of the template. SYBR Green dye intercalation into
the minor groove of double-stranded DNA reaches an emission
maximum at 530nm. Relative RNA equivalents for each
sample were calculated by either comparing to human or
mouse GAPDH levels. Five to six samples per group were run
in duplicate. Statistical analysis was performed by Student’s
t-test.
Preparation of alginate beads encapsulated endostatins
and tumour growth inhibition studies
Alginic acid extracted from Macrocystis pyrifera was purchased
from Sigma Chemicals, St. Louis, MO. A measure of 4% (w/v) of
alginic acid in water was sterilised by autoclaving. Endostatin
preparations or PBS (control) made in 1.5% alginic acid were
dropped gently into 0.1 M CaCl2 solution using a fine needle under
aseptic conditions. Beads were kept at 41C overnight and were
washed with sterile water before the subcutaneous implantation
into tumour-bearing mice. Entrapment efficiency was calculated
by determining the amount of protein remaining outside the beads
from the total protein using the BCA protein assay kit
(Pierce, Rockford, IL, USA). Logarithmically growing LS174T cells
were harvested by trypsinisation and suspended in serum-free
medium at a density of 1 10
7cellsml
 1. A measure of 100mlo f
the single-cell suspension was then subcutaneously injected into
the flanks of female athymic mice (6–8 weeks old). When the
tumours became visible (3 days after inoculation), mice were
randomised into groups and treated with endostatin-encapsulated
alginate beads (five animals per group). Endostatins were
implanted at a distant site (about 2cm away) at a dose of
B20mgkg
 1 once a week. Tumour growth was monitored by
periodic caliper measurements. Tumour volume was calculated by
the following formula: tumour volume (mm
3)¼(a b
2)/2, where
‘a’¼length in mm, ‘b’¼width in mm. Statistical significance
between control and treated groups was determined by Student’s
t-test.
RESULTS
Preparation and structural analysis of P125A endostatin
Native human endostatin and a mutant with a proline to alanine
substitution at position 125 were cloned and expressed in P.
pastoris. The P125A mutation did not change the binding of
endostatin to heparin. Like native human endostatin, P125A-
endostatin bound to a heparin–ceramic column and eluted at
around 300mM NaCl concentration, indicating similar binding
strength to heparin (data not included).
An NGR-sequence capable of targeting endothelial cells is
located immediately following the P125A-mutation site. Confor-
mational features surrounding the mutation site are shown in
Figure 1A. Crystallographic data published by Ding et al (1998)
show that P125 is located in a loop flanked by two b-sheets. In
order to determine whether the mutant protein was folded
properly, gross secondary structural analysis of the P125A mutant
was compared to the native protein made in the same expression
system. The CD spectra of native and P125A human endostatin
showed identical profiles, indicating that the two proteins have
similar gross secondary structures (Figure 1B).
P125A mutation-enhanced endothelial cell binding
The biological characteristics of P125A-endostatin were compared
to those of the native protein in a number of assays. As a first step,
the ability to bind endothelial cells was assessed using cell-
attachment assays. Gelatin (0.2%)-coated wells were used as a
control, with the number of cells (HUVEC) attached to gelatin-
coated wells taken as 100% to calculate relative binding. By this
standard, 38.5% of HUVEC attached to endostatin-coated wells.
Under similar conditions, a significantly higher number of HUVEC
(71%) bound to wells coated with P125A-endostatin (Figure 1C)
(P¼0.005). The observed differences in cell attachment are not
due to variation in coating efficiencies, which were determined by
ELISA method.
Inhibition of endothelial cell migration
A possible consequence of increased binding is increased
biological activity. Previously, we showed that P125A-endostatin
inhibited endothelial cell proliferation more efficiently than native
endostatin did (Calvo et al, 2002). Endothelial cell migration assay
is a more sensitive parameter to assess the biological activity of
endostatin. Therefore, bFGF-induced migration of endothelial cells
was determined in the presence of native and P125A-endostatin.
Similar to the proliferation assays, this mutant endostatin was
more effective than native protein in inhibiting cell migration
(Figure 1D). At all three concentrations tested, P125A-endostatin
inhibited endothelial cell migration more efficiently than native
endostatin.
Table 1 Primer sequences used for real-time PCR
Probe name Forward primer Reverse primer
Human VEGF AATGACGAGGGCGTGGAGT TTGATCCGCATAATCTGCATG
Human bFGF TGAATCACTAACTGACTGAAAATTGA GAAGGGTCTCCCGCATACT
Human Ang 1 CCTTCCAGCAATAAGTGGTAGTT CAAACGGCTCCAGATTCA
Human IL-8 TTTAGCATAGCTGGACATTAAAGAG GCAAATATGCTTAGGCTTTAACC
Human GAPDH CCACCCATGGCAAATTCCATGGCA TCTACACGGCAGGTCAGGTCCACC
Mouse flt-1 GTCGGCTGCAGTGTGTAAGT TGCTGTTCTCATCCGTTTCT
Mouse flk-1 TGTCAAGTGGCGGTAAAGG CACAAAGCTAAAATACTGAGGACTTG
Mouse tie-2 CGGCCAGGTACATAGGAGGAA CCCCCACTTCTGAGCTTCAC
Mouse endoglin GCAGGCAAGAACTCAGACAT AGCTCCCTCAGCTTCTGTTT
Mouse GAPDH ATGTTCCAGTATGACTCCACTCACG GAAGACACCAGTAGACTCCACGACA
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To assess whether the improved endothelial cell binding in vitro
can translate into enhanced tumour homing in vivo, tumour
localisation studies were performed. Endostatin and P125A-
endostatin were injected subcutaneously into human colon
cancer-bearing athymic mice. Tumour, lung, liver and serum
samples were collected. Relative levels of endostatin in the tissues
are shown in Figure 1E. Native endostatin accumulated in the
tumour tissues at a level of 3.0% when compared to serum levels.
P125A-endostatin, on the other hand, was found at a more than
three-fold higher concentration in the tumour tissue (10.22%
compared to serum levels). This difference was statistically
significant (P¼0.03). While the liver showed negligible amounts
of endostatins, lung tissues had significant accumulation of both
native and mutant endostatin. However, lung tissues did not show
any statistical difference between native and P125A-endostatin
accumulation.
Effect of endostatin and P125A-endostatin on
aminopeptidase N activity
As the mutation site is immediately followed by NGR motif, we
next tested whether the mutant endostatin has aminopeptidase N
inhibitory activity. Cellular extracts of aminopeptidase N enzyme
were prepared from HUVEC. These cells express 8–10 times
higher levels of aminopeptidase N compared to cancer cells such as
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Figure 1 Characterisation of P125A–endostatin–increased binding and biological activity. (A) Structural details surrounding the mutation site are shown.
Swiss PDB Viewer programme was used to generate the figure based on the structural information published by Ding et al (1998). P125 is followed by
N126, G127, and R128. (B) Circular dichroism spectroscopy of endostatin (---) and P125A-endostatin (—). (C) Cell attachment assay. Single-cell
suspension of HUVEC, prelabelled with 5(6)-CFDA, was added into triplicate wells coated with either endostatin or P125A-endostatin at a concentration of
1nmolwell
 1. Wells coated with 0.2% gelatin were used as maximum attachment (100%). Bound cells were quantified by a fluorescence plate reader.
Values represent mean of two independent experiments. Data are expressed as a mean (columns)7s.d. (bars). Statistical significance was determined by
Student’s t-test. **Po0.01. (D) Effect of endostatin (open bars) and P125A-endostatin (closed bars) on endothelial cell (HUVEC) migration. Basic FGF
(25ngml
 1) was used to induce migration of endothelial cells. Data are expressed as a mean (columns)7s.e. (bars). Statistical significance was determined
using Student’s t-test. *Po0.05, **Po0.01. (E) Tumour Localisation. Human colon carcinoma cells (LS174T) were injected s.c. into female athymic nude
mice. When the tumour size was around 500mm
3 (10 days after inoculation), Endostatin (open bars) or P125A-endostatin (closed bars) was injected at a
dose of 20mgkg
 1 subcutaneously. Endostatin levels were determined by ELISA. Endostatin levels are expressed as a percent of serum levels.
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cell line), MA148 (human ovarian cancer cell line) and LS174T
(human colon carcinoma cell line). Confluent HUVEC lysate
showed about three times higher activity than proliferating
HUVEC lysate (data not shown).
The data in Figure 2A show the effect of endostatin and its
mutant on aminopeptidase N activity. As a positive control, the
same concentration of bestatin, a known inhibitor of aminopepti-
dase N, was included. Bestatin inhibited 35% of the enzymatic
activity under the experimental conditions used. Leupeptin, a
negative control, did not inhibit the enzyme. Interestingly, neither
the native nor the P125A mutant showed any inhibition of
aminopeptidase N activity even at 5mM concentration.
In a separate experiment, we tested whether synthetic peptides
consisting of the amino acid sequence flanking the normal or
mutated position 125 (S118-T131) could inhibit aminopeptidase N
(Figure 2B). Interestingly, both peptides (native and mutant)
inhibited aminopeptidase N activity more effectively than bestatin.
At a concentration of 5mM, the mutant and native peptide inhibited
aminopeptidase N by 71.2 and 69.2%, respectively. These studies
suggest that the NGR motif in intact endostatin molecules
constructs may not be accessible to interact with aminopeptidase
N.
To confirm our findings, we characterised the interaction
between endostatins and aminopeptidase N in an immunoabsorp-
tion assay using antibodies to human aminopeptidase N enzyme.
Both synthetic peptides (A125 and P125) corresponding to the
region S118-T131 were capable of binding to aminopeptidase N, to
similar levels. However, intact proteins (native and P125A-
endostatin) did not show any detectable binding to aminopepti-
dase N (data not included). These results further confirm that the
NGR motif in endostatin is not accessible for binding to
aminopeptidase N.
Antiangiogenic activity of P125A-endostatin
Next, we determined the ability of endostatin and P125A-
endostatin to inhibit human colon cancer cell-induced angiogen-
esis in vivo using matrigel plug assays. Both endostatin and P125A-
endostatin inhibited angiogenesis stimulated by LS174T colon
carcinoma cells (Figure 3). Histological investigation of matrigels
from control and treated (native or mutant endostatin) animals
showed higher tumour cell density interspersed with well-
developed blood vessels in control matrigels when compared to
endostatin-treated groups. Endostatin-treated groups showed
some of the tumour cells organised into islands. (Figure 3B, C,
E, and F) when compared to control group treated with PBS
(Figure 3A and D). Anti-CD31 staining of frozen sections showed
quantitative difference between control and treated groups
(Figure 4).
The overall indicators of angiogenesis, such as microvessel
density (MVD), number of blood vessel ends (Ends), nodes
(branch points), and length, showed that both endostatin and
P125A-endostatin treatment significantly inhibited angiogenesis in
vivo (Figure 3H, I and Figure 4). Furthermore, endostatin
treatment seemed to alter angiogenic growth factor expression in
the tumour cell microenvironment. Cryostat sections of matrigels
showed reduced amounts of VEGF in immunofluorescence studies
using a polyclonal antibody made against human VEGF165 (Figure
3K and L). Reduced VEGF levels may be a reflection of reduced
number of tumour cells in the matrigel following endostatin
treatment or due to an indirect effect of endostatin-mediated
changes in the microenvironment.
Downregulation of angiogenic factors and receptors by
native and P125A-endostatin
Previously, we showed that the mammary gland of P125A-
endostatin-treated C3(1)/SV40 transgenic mice exhibited de-
creased mRNA levels of VEGF, angiopoietin-2, flk-1, flt-1, tie-1
and cadherin-5 when compared to PBS-treated control. In the
present study, a different model system was used to determine
selective changes in tumour-induced neovascularisation. Matrigel
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Figure 2 Effect of endostatin and synthetic peptides on aminopeptidase
N activity. (A) Aminopeptidase N was extracted from HUVEC cultures.
Bestatin was used as a positive control, and leupeptin treatment served as a
negative control. Values represent mean of two independent experiments.
(B) Two polypeptides containing 14 amino-acid residues (S118–T131)
spanning the mutation site P125 were synthesised. One of the peptides had
the native sequence and the other contained P to A substitution. Both
peptides included the NGR motif. K, SR1 peptide (P125A); J, SR2
peptide (native sequence); m, bestatin.
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splugs do not contain any other host cells or vasculature at the
beginning of the experiment. Therefore, this model system is good
to assess changes in tumour cell microenvironment following
antiangiogenic therapy. To determine whether endostatin treat-
ment altered RNA levels of proangiogenic factors from tumour and
host receptors in newly formed blood vessels, real-time PCR was
performed using total RNA isolated from the matrigel samples.
Proangiogenic factors were detected by human gene-specific
primers, and receptors were detected by mouse gene-specific
primers (Table 1).
Results shown in Figure 5 demonstrate that mRNA levels of
major proangiogenic growth factors (tumour cell derived) and
receptors expressed on host endothelial cells were downregulated
by endostatin or P125A-endostatin treatment. Moreover, VEGF
and Ang1 expression were significantly decreased by P125A-
endostatin when compared to native endostatin. Angiopoietin 2
transcript was not detected in any of the samples analysed. Basic
FGF-related transcript levels were equally decreased by both the
native and mutant endostatin.
Target receptors for the tumour-derived angiogenic factors are
located on the host vascular endothelial cells. Therefore, mouse-
specific primers were used to study the levels of receptor molecules
for VEGF and Ang1. These studies showed that both native and
P125A-endostatin decreased mRNA levels of flt-1, flk-1, tie-2 and
endoglin, a coreceptor for TGF-beta. Although native endostatin
showed a slightly better effect when compared to the mutant
protein in decreasing flk-1 and flt-1, the differences were not
statistically significant.
Inhibition of tumour growth by endostatin and P125A-
endostatin
Microencapsulated endostatin is more effective than bolus
administration. In our previous studies, we showed that alginate
beads of P125A-endostatin was more effective in inhibiting MA148
ovarian cancer growth when compared to the native protein given
under similar condition (Calvo et al, 2002). These results were
confirmed in a human colon cancer model system (Figure 6).
LS174T colon cancer cell line, which was used in the previous
matrigel plug assay, grows aggressively in athymic mice and visible
tumours can be seen as early as 3 days after subcutaneous
injection. Endostatins encapsulated in alginate beads were given
twice on days 3 and 10 at a dose of 20mgkg
 1. Although native
endostatin exhibited only a marginal inhibition of LS174T tumour
growth, P125A-endostatin treatment resulted in significantly
enhanced antitumour activity. At the end of the experiment,
native endostatin showed 30% inhibition of tumour growth, but
P125A-endostatin decreased tumour size by 75% when compared
to PBS-treated control animals. These studies confirm that P125A-
endostatin inhibits tumour growth more effectively than the native
protein.
Figure 3 Histological analysis of matrigel plugs. Matrigel plugs containing LS174 human colon cancer cell line were used to determine the effect of
endostatin and P125A-endostatin on angiogenesis. ((A)–(F)) Show H&E staining; ((A)–(C)) 100 magnification, ((D)–(F)) 400 magnification, Green
squares in ((A)–(C)) indicate the area of the images in  400 magnification of ((D)–(F)). ((G)–(I)) Show vessel staining with anti-CD31 antibody (red)
and nuclei staining with DAPI (blue)  200 magnification; ((J)–(L)) VEGF expression detected by indirect immunofluorescence using FITC-conjugated
antibodies (green) with DAPI (blue). ((A), (D), (G), (J)) control; ((B), (E), (H), (K)) native endostatin-treated matrigel sections; ((C), (F), (I), (L)) P125A-
endostatin-treated matrigel sections.
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Human endostatin is a proteolytic fragment of collagen type XVIII
(O’Reilly et al, 1997) and is generated in situ by elastase (Wen et al,
1999) and in the corneal epithelial cells by the action of matrilysin,
MMP-7 (Lin et al, 2001). The a-1 chain of collagen XVIII is
characterised by 10 domains of typical, triple-helical collagenous
repeats separated by short noncollagenous regions (Oh et al, 1994).
The carboxyl terminus 315 or 313 residues (mouse and human,
respectively) are noncollagenous and form the NCI domain.
Proteolytic processing of this domain results in the release of the
C-terminal 183 or 181 residues of the NCI domain, endostatin.
Collagen XVIII and its three splice variants are expressed in a
tissue-specific manner and localised to the perivascular basement
membrane. Endostatin-like sequence is also found at the C-
terminal end of a-1 chain of collagen type XV (Ramchandran et al,
1999). Protein fragments from the NC1 domains of a-1 chain
(arrestin), a-2 chain (canstatin) and a-3 chain (tumstatin) of
collagen type IV are also effective in inhibiting angiogenesis and
tumour growth (Kamphaus et al, 2000).
Recombinant mouse and human endostatins have been cloned
and expressed (Dhanabal et al, 1999). In a number of model
systems, endostatin treatment either inhibited or regressed
experimental tumours (O’Reilly et al, 1997). In some studies, only
moderate inhibition was observed (Dhanabal et al, 1999;
Yokoyama et al, 2000). Understanding the basis for these
discrepancies may help in the successful clinical development of
endostatins. Alternatively, structure/function studies can be used
to generate more potent angiogenic inhibitors. Proline 125 is
located in a b-hairpin loop between the b sheets K and L of human
endostatin. An endothelial cell homing motif, NGR, is located
immediately following this mutation site in human endostatin. In
mouse endostatin, however, the SGR sequence is seen in place of
NGR. The NGR motif was originally identified while mining for
sequences capable of homing to tumour vasculature using Phage
display libraries (Pasqualini et al, 2000). In spite of the
nonconservative substitution of a proline to alanine, the mutant
protein was expressed in soluble form and was biologically active.
The CD spectrum showed that P125A-mutation did not cause
major structural change. Asn-Gly-Arg-containing peptides are
known to inhibit endothelial cell membrane-associated amino-
peptidase N activity. However, neither the native nor the mutant
8000
* *
* *
* *
* *
* * *
*
*
* *
6000
4000
2000
0
300
200
80
60
40
20
0
100
100
75
50
25
0
0
P
i
x
e
l
 
c
o
u
n
t
B
r
a
n
c
h
 
p
o
i
n
t
s
 
(
n
o
d
e
s
)
T
o
t
a
l
 
v
e
s
s
e
l
 
l
e
n
g
t
h
 
V
e
s
s
e
l
 
 
e
n
d
s
N
a
t
i
v
e
 
e
n
d
o
s
t
a
t
i
n
P
1
2
5
A
-
e
n
d
o
s
t
a
t
i
n
C
o
n
t
r
o
l
C
o
n
t
r
o
l
N
a
t
i
v
e
 
e
n
d
o
s
t
a
t
i
n
P
1
2
5
A
-
e
n
d
o
s
t
a
t
i
n
C
o
n
t
r
o
l
N
a
t
i
v
e
 
e
n
d
o
s
t
a
t
i
n
P
1
2
5
A
-
e
n
d
o
s
t
a
t
i
n
C
o
n
t
r
o
l
N
a
t
i
v
e
 
e
n
d
o
s
t
a
t
i
n
P
1
2
5
A
-
e
n
d
o
s
t
a
t
i
n
AB
CD
Figure 4 Inhibition of angiogenesis by native and mutant endostatin. A
total of 7–10 frames of matrigel sections stained with anti-mouse CD31-PE
were captured per sample and then analysed for microvessel density. (A)
pixel density; (B) blood vessel ends (Ends); (C) branch points (nodes); (D)
vessel length. Statistical significance was determined using Student’s t-test.
**, Po0.01; *, Po0.05. The error bars indicate s.e.
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Figure 5 Downregulation of proangiogenic growth factors and
receptors by endostatin treatment. Real-time PCR data were normalised
by mRNA level to GAPDH. Data show relative mRNA levels. Messenger
RNA of human proangiogenic factors (VEGF, bFGF, Ang1 and IL8) and
mouse receptors (flt-1, flk-1, tie-2 and Endoglin) in Matrigel plugs were
downregulated by endostatin and P125A-endostatin treatment.
Mutant endostatin
Y Yokoyama and S Ramakrishnan
1633
British Journal of Cancer (2004) 90(8), 1627–1635 & 2004 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sprotein showed any detectable inhibition of aminopeptidase N.
Although synthetic peptides corresponding to this region showed
potent inhibition of aminopeptidase N, these studies suggest that
the internal NGR sequence in endostatin is constrained and not
accessible to bind aminopeptidase N. Furthermore, inhibition of
this enzyme may not be directly relevant to the biological activity
of endostatin since mouse and human endostatin have different
sequences (SGR and NGR, respectively).
Endostatin binds to two distinct classes of proteins on the
endothelial cell surface. a5b1/avb3 integrins and heparin sulphate-
glycosaminoglycan component of the glypican have been reported
to be direct targets for endostatin. The domains of endostatin,
which are involved in binding the target molecules on endothelial
cell surface, have not been completely characterised. The heparin-
binding domain of endostatin is composed of a number of
positively charged arginine residues (Yamaguchi et al, 1999).
There are 15 arginine residues in mouse endostatin of which 14 are
conserved in human endostatin. In fact, synthetic peptides
emcompassing these arginine regions showed antiangiogenic
properties (Kasai et al, 2002). Other reports showed that
mutagenesis of some of the arginine residues either individually
or in pairs changed their affinity to heparin. These changes,
however, did not affect the biological activity significantly (Sasaki
et al, 1999; Yamaguchi et al, 1999). Our studies show that the
P125A-mutation does not affect heparin binding. This conclusion
is based on the NaCl concentration required to elute native and
mutant protein from heparin affinity column.
However, cell attachment assays showed that P125A-endostatin
bound more avidly than native endostatin. Enhanced binding to
endothelial cells led to improved biological activity, indicated by
the results of endothelial cell proliferation and migration assays. In
both the assays, the P125A-mutation increased bioactivity of
endostatin. Enhanced binding to endothelial cells also led to
improved tumour localisation of endostatin. The homing specifi-
city of endostatin to tumours compared to lung or liver tissue was
also improved by P125A-mutation. It is interesting that only
tumour accumulation was changed by P125A mutation. These
results suggest that the target molecule for P125A is perhaps
upregulated in tumour vasculature, thereby facilitating higher
binding.
Higher tumour homing also coincided with better in vivo
activity in matrigel plug assay. Treated matrigels showed tumour
cells forming glandular structures. Recently, Hajitou et al also
reported a similar finding. Endostatin or angiostatin delivered by
adenoviral vectors inhibited local invasion and tumour vascular-
isation of transplanted murine malignant keratinocytes (Hajitou
et al, 2002).
Real-time PCR data showed that mRNA levels of proangiogenic
factors and receptors were downregulated by endostatin treatment,
with VEGF and Ang1 downregulated more by P125A-endostatin
when compared to native endostatin. Histochemical analysis also
showed that VEGF protein levels were decreased in endostatin or
P125A-endostatin-treated tumour tissues. Our results are in
agreement with those of Calvo et al (2002) who showed, in the
C3(1)/SV40 transgenic mouse model, that P125A-endostatin
treatment suppressed mRNA and protein levels of VEGF, Female
C3(1)/SV40 mice treated with P125A-endostatin for a 3-week
period showed significant delay in tumour development, reduced
tumour burden and increased survival (Calvo et al, 2002). Hajitou
et al (2002) also showed 3–10-fold downregulation of VEGF
mRNA expression in endostatin-treated aortic ring. These results
indicate that endostatin affects proangiogenic factor expression in
the tumour microenvironment.
Slow release of endostatin by alginate encapsulation was used to
determine antitumour efficacy. Unlike the bolus injection protocol,
alginate-entrapped endostatin was given once a week. This method
reduced the cumulative dose to be given to each mouse by seven-
fold. Kisker et al (2001) also showed that continuous administra-
tion using a miniosmotic pump increased the potency of
endostatin therapy. Present studies clearly demonstrate that
P125A-endostatin inhibits colon carcinoma growth more effec-
tively when compared to the native endostatin.
In summary, these studies show that human endostatin can be
genetically modified to improve its ability to bind and inhibit
endothelial cells. Higher binding also coincided with changes in
potency in inhibiting cell proliferation and migration, and in
homing to tumours. Such differences in tumour-homing proper-
ties can contribute to improved antitumour activity of mutant
endostatin.
The mechanism of enhanced binding to endothelial cells of
P125A-endostatin still not entirely clear. It is likely that binding to
glypican (supported by heparin-binding data) is not altered by
P125A mutation. However, the P125A mutation may expose
cryptic determinants in endostatin, which can in turn bind to
novel target molecules on endothelial cells. Such an interaction
may enhance binding of P125A-endostatin to endothelial cells. We
initially hypothesised that aminopeptidase N could be a potential
target for P125A-endostatin. However, our current studies clearly
demonstrated that P125A-endostatin did not bind to aminopepti-
dase N. Further work will be necessary to understand the
molecular target and mechanism of enhanced binding of P125A-
endostatin to endothelial cells.
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Figure 6 Improved inhibition of tumour growth by P125A-Endostatin.
Human colon carcinoma cell line, LS174T was injected s.c. into female
athymic mice. After tumours reached a palpable size, mice were treated
with endostatin and P125A-endostatin encapsulated in alginate beads (s.c.)
at a dose of 20mgkg
 1week
 1. Endostatins were administered two times
1 week apart to colon cancer-bearing mice. Arrows denote time points at
which microencapsulated endostatins were administered. Two endostatin
treatments were given 1 week apart: &, alginate bead control (PBS); J,
endostatin; K, P125A-endostatin. The mean tumour volume of control
and treated groups are shown. Statistical significance was determined using
Student’s t-test. *Po0.05, **Po0.01. The error bars indicate s.e.
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